Reata Pharmaceuticals
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 48.1m | 53.6m | 26.5m | 9.0m | 11.5m | 2.2m | - |
| % growth | - | 12 % | (51 %) | (66 %) | 27 % | (81 %) | - |
| EBITDA | (45.8m) | (73.9m) | (284m) | (225m) | (244m) | (269m) | (346m) |
| % EBITDA margin | (95 %) | (138 %) | (1072 %) | (2497 %) | (2119 %) | (12140 %) | - |
| Profit | (47.7m) | (80.5m) | (290m) | (248m) | (297m) | (312m) | (358m) |
| % profit margin | (99 %) | (150 %) | (1094 %) | (2747 %) | (2588 %) | (14075 %) | - |
| EV / revenue | 13.1x | 26.3x | 232.7x | 404.3x | 21.5x | 273.5x | - |
| EV / EBITDA | -13.7x | -19.1x | -21.7x | -16.2x | -1.0x | -2.3x | - |
| R&D budget | 71.3m | 97.3m | 128m | 159m | 156m | 170m | - |
| R&D % of revenue | 148 % | 182 % | 483 % | 1764 % | 1358 % | 7664 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$1.6m | Series A | ||
| N/A | $3.6m | Series B | |
$12.0m | Series C | ||
$7.1m | Series D | ||
$25.0m | Series E | ||
| N/A | $30.7m | Series F | |
| N/A | $17.0m | Late VC | |
| N/A | $2.0m | Late VC | |
$78.0m | Growth Equity VC | ||
| N/A | $300m | Growth Equity VC | |
| N/A | $60.5m | IPO | |
$35.0m | Post IPO Debt | ||
* | N/A | $248m | Post IPO Equity |
* | N/A | $505m | Post IPO Equity |
* | N/A | $350m | Post IPO Equity |
* | N/A | $275m | Post IPO Debt |
* | $7.3b Valuation: $7.3b 3294.2x EV/LTM Revenues -27.1x EV/LTM EBITDA | Acquisition | |
| Total Funding | $477m | ||
Related Content
Recent News about Reata Pharmaceuticals
EditReata Pharmaceuticals is a biopharmaceutical company that focuses on developing innovative therapies for serious, life-threatening diseases. The company's primary market is the healthcare sector, specifically patients suffering from conditions such as diabetic peripheral neuropathic pain (DPNP) and Friedreich’s ataxia.
Reata's business model revolves around the research, development, and commercialization of pharmaceutical products. The company has an approved product, aSKYCLARYS (omaveloxolone), which is sanctioned by the U.S. FDA for use. Additionally, Reata has a robust pipeline of drug candidates in various stages of development. These include Cemdomespib, RTA 415, and RTA 417, which are currently investigational drugs, meaning their safety and efficacy are yet to be established by any regulatory agency.
Reata generates revenue through the sale of its approved products and potentially from the future sales of its pipeline drugs once they receive regulatory approval. The company also plans to initiate a Phase 2 trial of Cemdomespib in patients with DPNP in the third quarter of 2023, which could potentially lead to additional revenue streams if the trial is successful and the drug receives approval for commercial use.
In February 2021, the company received a petition from the Friedreich’s ataxia community to submit a New Drug Application (NDA) for omaveloxolone, indicating a strong demand for innovative treatments in this area. The FDA has also accepted for filing Reata’s first NDA of bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport Syndrome, further expanding the company's potential market.
Keywords: Biopharmaceutical, Innovative Therapies, Serious Diseases, Healthcare Sector, Drug Development, Commercialization, Investigational Drugs, Revenue Generation, New Drug Application, Chronic Kidney Disease.